Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CEL-SCI Corporation (CVM)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
4.6200-0.6100 (-11.66%)
At close: 04:00PM EDT
4.7500 +0.13 (+2.81%)
After hours: 06:52PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • G
    Gains
    When the volume picks up, we will again end the day in the GREEN!
    Bullish
  • C
    Chuck
    Think we'll finish near $5 today? #optimistic
  • A
    Andy
    On January 1, 2020, ClinicalTrials.gov will update posting procedures for submitted results information for applicable clinical trials. Consistent with 42 CFR Part 11, the National Library of Medicine (NLM) will publicly post submitted results information within 30 days of submission, regardless of whether the quality control (QC) review process is complete.
    ****Study records with results submitted but not yet posted on ClinicalTrials.gov include a Results Submitted tab (in place of the No Results Posted tab) to help users track the submission and QC review status of results information. The tab displays a table of dates showing when results information was submitted and, if applicable, returned to the responsible party with QC review comments identifying at least one major issue. In addition, the following dates are summarized on the Key Record Dates page for each record:
    **********First Submitted that Met QC Criteria
    **********Results First Submitted that Met QC Criteria
    **********Last Update Submitted that Met QC Criteria
  • M
    Mitch
    Good Morning to all my fellow CVM'ers.

    I just bought more shares...
  • C
    Codfather_59
    excellent data.

    now we move to marketing.
  • G
    Gains
    The truth is that most Biotech stocks fail. As a result, you have people that make a living shorting Biotech stock that they have no knowledge of at all. They simply short 100 different companies and 95 of them fail. It's a numbers game to most that play that game with no research on their part
    Here we actually have the real goods, and it will go to market, yet the gamers still have to play their best game by bashing every chance they get.
    The truth shall prevail, and we believe!
  • A
    Anthony
    No one has EVER shown survival benefit in advanced primary head and neck Cancer! The 16% who had a partial or complete tumor response in 3 weeks vs. 0 in the control group explain most of it. No one can argue that Multikine has no effect. It is a direct effect! Then, on top of that, Cel-Sci has shown with an amazing statistical data that anyone who has a tumor response has MASSIVELY improved survival. Other indicators also support this. Understanding all of this is now occurring...
  • C
    Codfather_59
    this should be a BIG week for us assuming the NLM doesn't play games over apostrophes and commas.
    maybe over then this week.
    get ready, there's a train a coming!
  • P
    Positive
    Pre-Market ploy won't work this time....sorry but nice try!
  • D
    David
    Which begs the question WHERE are they gonna get the shares ?

    only100 shares on the ask No shares available to cover Millions and Millions sold short
  • J
    Jerry
    New EF Hutton report out today with $17 PT.
    Bullish
  • D
    David
    this is what started the panic short covering and debunked and destroy CVM short thesis

    In the ITT population as a whole, 8.5% of all Multikine-treated patients had a tumor response before surgery, but not a single tumor response before surgery was seen in the ITT control group before surgery, statistically a highly significant finding (p-value of less than 0.00000000001). This indicates that the likelihood of seeing these results by chance is less than 1 in ten billion. These results confirm findings from the Phase 1 and 2 studies with Multikine and provide direct evidence of Multikine’s anticancer activity.
  • B
    Bob
    Just 14 days ago Nastradamus .... aka "Sushi" was broadcasting live from his jet ski that " I see $2s soon."

    Wrong again!

    Mr Magoo ( remember him) seems to be so obsessed with the Pre-Bla. He's got blinders on?

    It's really all about complete data and it's coming soon!
  • C
    Chuck
    Hmm...so now that my optimistic prediction hit the $5 mark, dare I say we'll hit $7 by Thursday/Friday of this week? :)
  • M
    Mark
    Five patients in the study had their tumors completely disappear (confirmed by pathology) before surgery.
  • C
    Codfather_59
    i wonder, was there a leak from the national library of medicine?

    the data is due for publishing. 30 days runs out this week and we see this.
    volume has been low until today and it sure looks like short covering.

    could they have a mole in the NLM? why not?

    let's see what happens today!
  • R
    Rodgers Make Believe
    Looks like I will be buying tommorrow
    Bullish
  • J
    Jerry
    EF Hutton:

    "We expect to learn more over the next few months and remind investors that the
    entire process of clinical trials, peer reviews, the full release of data and the Biologics
    License Application (BLA) steps takes a long time.

    We reiterate our Buy rating and $17.00 price target. We remain optimistic that positive
    news flow about Multikine immunotherapy could unfold over the next few months."
    Bullish
  • J
    Just  my epinion
    Five patients in the study had their tumors completely disappear (confirmed by pathology) before surgery. In the ITT population as a whole, 8.5% of all Multikine-treated patients had a tumor response before surgery, but not a single tumor response before surgery was seen in the ITT control group before surgery, statistically a highly significant finding (p-value of less than 0.00000000001). This indicates that the likelihood of seeing these results by chance is less than 1 in ten billion. These results confirm findings from the Phase 1 and 2 studies with Multikine and provide direct evidence of Multikine's anticancer activity.Additional results from the Phase 3 study of Multikine in advanced primary head and neck cancer have been submitted to the U.S. government clinical trial website www.clinicaltrials.gov. That data is expected to be released to the public in the near future.CEL-SCI's dedicated current Good Manufacturing Practice (CGMP) facility in which it manufactures Multikine is now undergoing validation following the completion of its commercial scale build out during the first quarter of 2022. The construction was designed to ensure the facility will be compliant with all U.S. Food and Drug Administration's (FDA) GMP and European regulations.
  • J
    Jeff w
    Market will be putting in lots of over-time for tonight and tomorrow 🧐🧐
    Bullish
Advertisement
Advertisement